Introduction Breast cancer is a global public health challenge. It is the most commonly diagnosed cancer and the leading cause of cancer-related death in women. Several inequalities remain among women facing this disease, depending on their country of birth and their sociodemographic characteristics. The SENOVIE study (Therapeutic mobility and breast cancer) aims to understand the life trajectories of women born in France and in sub-Saharan Africa treated for breast cancer in four hospitals in the greater Paris area.Methods and analysis The SENOVIE study is a mixed methods study, combining a quantitative and a qualitative approach. A quantitative retrospective life-event survey is conducted in four hospital centres in the greater Paris area, France, to (1) understand how breast cancer (diagnosis, treatment and possibly reconstruction) impacts the life trajectories of women in many spheres (migration, family life, professional life, financial situation, etc); (2) study the access to healthcare by women living with breast cancer and their determinants; and (3) examine how gender relations may shape breast cancer experience. Women born in France and women born in sub-Saharan Africa are recruited: 1000 women, including 500 per group. In the standardised, face-to-face questionnaire, each dimension of interest is collected year by year from birth until the time of the survey. Clinical and laboratory information is documented with a short medical questionnaire filled out by the medical teams. The qualitative survey is conducted specifically with women born in sub-Saharan Africa who came to France for treatment to better understand their trajectories and the specific obstacles they faced. To analyse the quantitative data collected, descriptive analyses will be used to visualise trajectories (sequence analysis), along with longitudinal analysis methods (survival models and duration models).Ethics and dissemination The study is conducted in accordance with the Declaration of Helsinki. The French Data Protection Authority (Commission Nationale de l’Informatique et des Libertés, declaration number 2231238) and the Committee for Persons’ Protection East I (Comité de Protection des Personnes Est I, national number 2023-A01311-44) approved it. We will disseminate the findings through scientific publications, policy briefs, conferences and workshops.Trial registration number The SENOVIE France study is registered on Clinicaltrial.gov (NCT06503393; registration date: 7 September 2024; https://clinicaltrials.gov/study/NCT06503393).

BACKGROUND:Breast cancer is the most prevalent cancer among women globally, including in Africa. Oncology is a relatively new discipline in many West African countries, particularly in Benin. There is currently a lack of data concerning the current state of cancer care infrastructure and oncology practices within these countries. The aim of the article is to describe the barriers and opportunities related to access to oncology care in Benin. METHODS:We employed a qualitative research design. Fifty-six semi-structured interviews were conducted with caregivers treating cancer (n=26), women with breast cancer (n=23), and representatives of associations (n=2). Additionally, 18 days of participant observation were conducted in a chemotherapy and palliative care departments in Cotonou, Benin. The data was analysed using Levesque et al.'s theoretical framework on access to healthcare. RESULTS:Women encounter obstacles such as delayed diagnosis and unequal access to information, as well as socio-cultural beliefs that favour traditional medicine and discourage surgical interventions like mastectomy. The treatment pathway is often chaotic due to insufficient specialised caregivers and limited infrastructure, with services centralised in Cotonou forcing patients to travel long distances around the country. The current lack of radiotherapy requires patients in need to travel abroad for treatment. High costs of biomedical tests and treatments often lead to care abandonment, worsening health inequalities. However, positive changes should be highlighted, such as the establishment of the Inter-University Diploma in Gynaecological and Breast Oncology in 2013, the expansion of palliative care services in the country, and the planned opening of the Calavi International Hospital Centre in 2025. Challenges include continuing to train health professionals in oncology, further developing health financing and supporting civil society to raise awareness of breast cancer. CONCLUSIONS:Benin is facing several challenges in relation to the provision of timely and high-quality care for women with breast cancer. However, there is a growing commitment to enhancing breast cancer care in Benin.

E-health solutions are a promising tool to assist patients in self-managing symptoms for various diseases. This study aimed to assess the feasibility, reliability, usability, and satisfaction of a digital medical device (ZEMY) for patients’ self-monitoring of symptoms commonly experienced during breast cancer treatment and to enhance interaction with healthcare professionals. In this open-label, interventional, multicentre, single-arm clinical trial (NCT03558490), patients at all stages of breast cancer initiating oral and/or parenteral treatment were recruited at initiation of therapy and followed for 3 months. During treatment, the patients reported 9 symptoms (diarrhoea, nausea/vomiting, fever/febrile neutropenia, fatigue, pain, cutaneous and mucosal toxicities, hypertension, anxiety/depression) through the ZEMY application, which provided self-management recommendations and sent message alerts to healthcare professionals. To reach the primary feasibility endpoint, more than 50

Introduction : La capacité des associations à renforcer le pouvoir d’agir des personnes immigrées en France et touchées par la maladie a bien été montrée dans le champ du VIH. Dans le domaine des cancers du sein, il est reconnu que les espaces associatifs participent aux processus d’acceptation de la maladie et de la reconstruction de soi mais on sait peu de choses sur le rôle de ces associations auprès des femmes immigrées en France. But de l’étude : Cet article propose de documenter le rôle des associations de lutte contre les cancers du sein dans les parcours spécifiques de femmes venues d’Afrique subsaharienne pour soigner leur cancer du sein en Île-de-France. À l’aide d’une méthodologie mixte (constitution d’une base de données et réalisation d’entretiens semi-directifs), nous avons quantifié le nombre d’associations présentes à Paris et dans la petite couronne, et documenté leur accessibilité pour ces femmes. Résultats : En 2021, 514 associations de lutte contre les cancers du sein ont leur siège social à Paris et dans les départements de la petite couronne francilienne. Les entretiens ont révélé leur manque de visibilité et de spécificité pour les femmes originaires d’Afrique subsaharienne. Conclusions : Les associations de lutte contre les cancers sont très nombreuses en Île-de-France mais elles sont peu accessibles et peu adaptées aux femmes originaires d’Afrique subsaharienne. Dans une perspective de lutte contre les inégalités sociales de santé, nous recommandons de créer des espaces d’énonciation de soi pour ces femmes, afin de soutenir leur parcours de vie, de soins et de reconstruction qui présentent des spécificités dans leur lutte contre la maladie.

Safety and effectiveness of T-DXd should be characterized in real world (RW) settings. We designed an observational study to address RW evidence gaps and highlight the first clinical experiences with T-DXd for HER2+ m/u BC pts. REALITY-01 is an ambispective phase IV study that includes HER2+ m/u BC pts who received T-DXd after ≥ 2 prior lines of anti-HER2+ treatments (tt) through an early access program or after marketing authorization. Interim analysis on safety and effectiveness data are presented. At data cut-off, 305 pts were enrolled in 56 centers (median follow-up of 17.7 months (mo)). At the start of T-DXd, median age was 59 years (17.7% pts were ≥ 70 years) and 22.1% (n=60) of pts had CNS metastasis (mCNS) including leptomeningeal disease. 69% (n=187) and 15.5% (n=42) of pts had ECOG 0-1 and ECOG 2-3. 51, 7% of pts received ≥4 lines before T-DXd. Median duration of T-DXd tt was 12.5 mo. Incidence and severity of T-DXd-related adverse drug reactions (ADR) of interest in general and a focus on interstitial lung disease (ILD) are presented in the table. Median progression free survival (mPFS) was 17.4 mo [95%CI: 15.6;19.6] and objective response rate was 49.7% [95%CI: 42.3;57.2], including 24.9% (n=46) of complete response (CR). For the study population, median overall survival (OS) was not reached. For pts with mCNS at inclusion, CNS response rate was 52.4% [36.4;68.0], including 19% (n=8) of CR.Table: 190PPrimary endpoint: Percentage of pts with at least one T-DXd related ADR of interest during the 2 years following the start of T-DXd administrationTotal n=305Total number of pts with any ADR n(%) [95%CI]240 (78.7) [73.7;83.1]Leading to T-DXdDose reduction44 (14.4)Discontinuation31 (10.2)Interruption66 (21.6)Any serious29 (9.5)Grades (worst grade)169 (22.6)266 (21.6)396 (31.5)44 (1.3)53 (1.0)Any ILD – no. (%)43 (14.1)114 (4.6)216 (5.2)37 (2.3)4053 (1.0) Open table in a new tab These first results from REALITY-01 confirm the safety and effectiveness of T-DXd in heavily pre-treated HER2+ m/u BC pts with or without mCNS and are consistent with DESTINY-Breast01/02 results.

Abstract Background: Breast cancer (BC), is a highly heterogeneous disease, divided into molecular subtypes based on gene expression and clinical outcomes. Transcriptomics profiling depicted a subtype that has luminal expression profile but lacks estrogen receptor (ER), progesterone receptor expression with an overlapping expression of HER-2; yet it overexpresses androgen receptor (AR). This subtype was referred to as MABC and constitutes 8-14% of all BC types. At present MABC is often misdiagnosed with triple negative BC (TNBC). Its improper diagnosis demands the adoption of complementary tools; miRNA, key players in BC tumorigenic processes, hold promise in defining MABC. Methods: 539 BC microarray data were downloaded from The Cancer Genome Atlas (TCGA-BRCA) (PMID: 25691825) using TCGA biolinks R/Bioconductor package (PMID:267704973). Cases with available miRNA data were retained and classified using citbcmst R package (PMID: 21785460). Differential expression analysis identified deregulated miRNAs using DEseq2. The validation set consists of 111 ER-neg samples (68 MABC, and 43 TN samples) with an average age at diagnosis 58.51 years and a median follow-up=78.5 months. MABC tumors were characterized apart of TNBC by the molecular signature (AR, FOXA1 and AR-related genes, PMID: 25516281) on fresh tissue sections. Using miRCURY LNATM miRNA PCR assay, miRNA profiling was done for a panel of differentially expressed miRNAs. Non tumorigenic (MCF-10A) and BC Cellular models MABC (MDA-MB-453) and TNBC (MDA-MB-231) were used to investigate the invasive potential of MABC. Results: TCGA data analysis indicated MABC as a separate entity based on gene signature. MiRNA-seq data analysis depicted a set of 6 significantly deregulated miRNA with absolute value of log2 fold change> 1 and P-adjusted value <0.05 between MABC and TNBC. We validated, by miRNA profiling, significant upregulation of miR-2115-3p and miR-187-3p in MABC compared to TNBC. These miRNAs significantly differentiate MABC patients from TNBC patients where the combined miRNA panel of miR-2115-3p and miR-187-3p had an area under the curve of 0.904 ±0.28 (P<0.0001 and 95% CI: 0.850-0.958) and sensitivity, specificity, and a diagnostic accuracy of 90.41%, 81.1%, and 86.5% respectively. Preliminary data, showed that non-tumorigenic/non-invasive MCF-10A had a significant increase in its invasive ability upon transfection with miR-187-3p mimic (P<0.05). Similarly, the invasive cell line MDA-MB-231 showed a significant increase in invasion upon transfection with miR-187-3p mimic (P<0.05). On the other hand, only miR-187-3p inhibitor significantly decreased the invasive potential of MDA-MB-453 cells (P<0.05). Conclusion: MABC has a unique signature of miRNA as compared to TNBC. miR-2115-3p, and miR-187-3p could be potential diagnostic biomarkers for MABC. The invasive potential of MABC could be attributed to miR-187-3p activity. Citation Format: Ghada Chamandi, Adrien Borgel, Abdallah Kurdi, Pierre Khoueiry, Luis Teixeira, Morgane Le Bras, Jacqueline Lehamnn, Rihab Nasr. microRNA (miRNA) a putative biomarker to better define the molecular apocrine breast cancer (MABC) subtype [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2987.